{
    "Clinical Trial ID": "NCT00149214",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Pemetrexed Plus Doxorubicin, Followed by Docetaxel",
        "  pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)",
        "INTERVENTION 2: ",
        "  Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel",
        "  cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically confirmed diagnosis of primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2-T4/N0-2.",
        "  Performance status 0-2 Eastern Cooperative Oncology Group (ECOG).",
        "  Adequate organ function (bone marrow, hepatic, renal, cardiac).",
        "Exclusion Criteria:",
        "  Prior anthracyclines as part of prior anticancer therapy.",
        "  Concurrent antitumor therapy.",
        "  Second primary malignancy.",
        "  Serious concomitant systemic disorder.",
        "  Pre-existing sensorial or motor neuropathy",
        "Grade 1."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With a Pathological Complete Response",
        "  pathological assessment of tissue removed during surgery to determine if tumor tissue is still present after chemotherapy",
        "  Time frame: surgery after eight 21-day cycles of chemotherapy",
        "Results 1: ",
        "  Arm/Group Title: Pemetrexed Plus Doxorubicin, Followed by Docetaxel",
        "  Arm/Group Description: pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)",
        "  Overall Number of Participants Analyzed: 127",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Pathological Complete Response: 21",
        "  Tumor Cells Still Present: 99",
        "Not evaluable: 7",
        "Results 2: ",
        "  Arm/Group Title: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel",
        "  Arm/Group Description: cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)",
        "  Overall Number of Participants Analyzed: 119",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Pathological Complete Response: 24",
        "  Tumor Cells Still Present: 89",
        "Not evaluable: 6"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 15/134 (11.19%)",
        "  Anaemia 0/134 (0.00%)",
        "  Chronic lymphocytic leukaemia 0/134 (0.00%)",
        "  Febrile neutropenia 4/134 (2.99%)",
        "  Leukopenia 4/134 (2.99%)",
        "  Neutropenia 1/134 (0.75%)",
        "  Cardiovascular insufficiency 0/134 (0.00%)",
        "  Myocardial infarction 0/134 (0.00%)",
        "  Diarrhoea 1/134 (0.75%)",
        "  Nausea 2/134 (1.49%)",
        "  Stomatitis 1/134 (0.75%)",
        "  Vomiting 3/134 (2.24%)",
        "Adverse Events 2:",
        "  Total: 25/123 (20.33%)",
        "  Anaemia 1/123 (0.81%)",
        "  Chronic lymphocytic leukaemia 1/123 (0.81%)",
        "  Febrile neutropenia 5/123 (4.07%)",
        "  Leukopenia 9/123 (7.32%)",
        "  Neutropenia 3/123 (2.44%)",
        "  Cardiovascular insufficiency 1/123 (0.81%)",
        "  Myocardial infarction 1/123 (0.81%)",
        "  Diarrhoea 1/123 (0.81%)",
        "  Nausea 0/123 (0.00%)",
        "  Stomatitis 0/123 (0.00%)",
        "  Vomiting 0/123 (0.00%)"
    ]
}